Also if you look at NDF broker report PYC commissioned last year from Stuart Roberts.
Medimmune/AstraZeneca, August 2010. This deal is focused on antimicrobial peptides. Initially the work was focused on finding new drugs to attack Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia. Medimmune paid US$0.75m upfront and committed to another US$0.75m in research funding for the first twelve months, while Phylogica can receive up to US$98m in milestones. Phylogica was able to show, early on in the collaboration, that its peptides could kill multi-drug resistant bacteria.
Ann: PYC Pivot to Platform - BioShowcase Presentation, page-19
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.045(3.63%) |
Mkt cap ! $749.4M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.29 | $1.25 | $337.0K | 265.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 58344 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |